A randomized-controlled pilot trial (NCT01304251) compared the toxicity of docetaxel, doxorubicin, and cyclophosphamide in HER2 negative breast cancer patients who followed STF for 48 h (24 h before and after chemotherapy) compared to patients with healthy nutrition. Here, ERBB2 is linked to breast carcinoma.